Vaping has risen among ex-smokers in England

Publicly released:
International
Photo by Sebastian Radu on Unsplash
Photo by Sebastian Radu on Unsplash

Vaping among adult ex-smokers in England has substantially increased over the past decade, according to a survey of over 54,000 adults which found a particularly pronounced increase in vaping prevalence among younger ex-smokers aged 18-25. The survey found the percentage of people using e-cigarettes to try to quit smoking increased from 26.9% in 2013 to 41.4% in 2024, while the percentage of participants who had recently stopped smoking but vaped increased from 1.9% to 20.4%. The proportion of vapers amongst ex-smokers who had quit more than a year ago was higher among younger participants, at 58.9% in 18-year-olds versus 10.7% among 65-year-olds. As the data does not capture e-cigarette users who have never smoked, the actual trend of vaping uptake could be higher. The researchers say the results show a significant spike in vaping following the introduction of disposable vapes in 2021, and add that more research is needed into how smoking relapse rates have changed in the context of vaping.

Media release

From: Springer Nature

Health: Higher e-cigarette uptake in English ex-smokers

E-cigarette use has substantially increased amongst adult ex-smokers in England over the past decade, reports a paper published BMC Medicine. The study, based on a survey of over 50,000 adults, observes a particularly pronounced increase in vaping prevalence among younger ex-smokers, particularly 18 to 25-year-olds.

E-cigarettes have become a common quitting method for smokers: in 2011, fewer than 1 in 100 quit attempts in England involved e-cigarettes. By 2014, this figure had risen to more than 1 in 4. The introduction of disposable e-cigarettes in 2021 correlates with a substantial rise in vaping in England across all smoking demographics.

Sarah Jackson and colleagues analysed data from the Smoking Toolkit Study, a cross-sectional survey of adults in England that polls approximately 1,700 newly selected individuals each month. This study focused on data from 54,251 ex-smokers surveyed between October 2013 and May 2024. It assessed the use of e-cigarettes in quit attempts among smokers who had tried to stop smoking at least once in the past year and current e-cigarette use among ex-smokers. The average age across the whole cohort was 49.2 years old, with 46.9% identifying as female. The percentage of people using e-cigarettes to try to quit smoking increased from 26.9% in 2013 to 41.4% in 2024, while the percentage of participants who had recently stopped smoking who vaped increased from 1.9% to 20.4%.

The proportion of vapers amongst ex-smokers who had quit more than a year ago was higher among younger participants, at 58.9% in 18-year-olds versus 10.7% among 65-year-olds. As the data does not capture e-cigarette users who have never smoked, the actual trend of vaping uptake in 18 to 25-year-olds may be higher. Vaping was also more common among ex-smokers who reported higher alcohol intakes, while there were no significant differences in vaping by gender.

The results demonstrate a significant spike in e-cigarette uptake among English ex-smokers, particularly following the introduction of disposable vapes in 2021. The authors add that more research is needed into how smoking relapse rates are changing in the context of vaping prevalence.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research Springer Nature, Web page The URL will go live after the embargo lifts.
Journal/
conference:
BMC Medicine
Research:Paper
Organisation/s: University College London, UK
Funder: This work was supported by Cancer Research UK (PRCRPG-Nov21\100002). SPECTRUM is a multi-university, multi-agency research consortium focusing on the commercial determinants of health and health inequalities, which is funded by the UK Prevention Research Partnership. JB is a co-investigator and leads a work package on developing and integrating new data sources to inform action. Competing interests: JB has received unrestricted research funding from Pfizer and J&J, who manufacture smoking cessation medications. LS has received honoraria for talks, unrestricted research grants and travel expenses to attend meetings and workshops from manufactures of smoking cessation medications (Pfizer; J&J), and has acted as paid reviewer for grant awarding bodies and as a paid consultant for health care companies. All authors declare no financial links with tobacco companies, e-cigarette manufacturers, or their representatives.
Media Contact/s
Contact details are only visible to registered journalists.